Donatella Marino

1.1k total citations · 1 hit paper
34 papers, 738 citations indexed

About

Donatella Marino is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Donatella Marino has authored 34 papers receiving a total of 738 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 12 papers in Hepatology. Recurrent topics in Donatella Marino's work include Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Colorectal Cancer Treatments and Studies (11 papers) and Pancreatic and Hepatic Oncology Research (9 papers). Donatella Marino is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Colorectal Cancer Treatments and Studies (11 papers) and Pancreatic and Hepatic Oncology Research (9 papers). Donatella Marino collaborates with scholars based in Italy, United Kingdom and United States. Donatella Marino's co-authors include Francesco Leone, Massimo Aglietta, Celeste Cagnazzo, Srinivasa R. Rao, Claire M. Edwards, Freddie C. Hamdy, Seint T. Lwin, Isabel R. Orriss, Roberto Filippi and Massimo Di Maïo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Donatella Marino

32 papers receiving 730 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

2023 136 citations Shukui Qin, Donatella Marino et al. profile →

Peers

Countries citing papers authored by Donatella Marino

Since Specialization

Citations

This map shows the geographic impact of Donatella Marino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donatella Marino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donatella Marino more than expected).

Fields of papers citing papers by Donatella Marino

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donatella Marino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donatella Marino. The network helps show where Donatella Marino may publish in the future.

Co-authorship network of co-authors of Donatella Marino

This figure shows the co-authorship network connecting the top 25 collaborators of Donatella Marino. A scholar is included among the top collaborators of Donatella Marino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donatella Marino. Donatella Marino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical relevance and methodological approach for the assessment of drug–drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF) 2025 ·ESMO Open ·Marzia Del Re, Rossana Roncato, Alberto Argentiero, Liberato Berrino, Andrea Botticelli, Annalisa Capuano, Samantha Di Donato, Stefano Fogli, Donatella Marino, (unknown), (unknown), Franco Perrone, Nicola Silvestris, Romano Danesi	2
2	Adoption of electronic patient-reported outcomes in cancer clinical practice: the point of view of Italian patients 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), (unknown), Donatella Marino, (unknown), Elisa Sperti, Valentina Tuninetti, Francesca Vignani, Clizia Zichi, Valentina Elisabetta Bounous, Giorgio Valabrega, Annamaria Ferrero, Nicoletta Biglia, Massimo Di Maïo	2
3	LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma 2022 ·Annals of Oncology ·Shukui Qin, Masashi Kudo, T Meyer, RS Finn, Peter Vogel, Yibing Bai, (unknown), Zhefeng Meng, (unknown), Takeshi Satoh, (unknown), Donatella Marino, Éric Assenat, Lucjan Wyrwicz, (unknown), (unknown), (unknown), (unknown), (unknown), Andrew X. Zhu	54
4	A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step? 2021 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Clizia Zichi, Donatella Marino, Elisa Sperti, (unknown), (unknown), F. De Vita, Massimo Di Maïo	3
5	Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence 2020 ·SHILAP Revista de lepidopterología ·(unknown), Donatella Marino, Massimo Di Maïo	1
6	<p>Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence</p> 2020 ·Cancer Management and Research ·Emmanuele De Luca, Donatella Marino, Massimo Di Maïo	26
7	Second-line treatment options in hepatocellular carcinoma 2019 ·Drugs in Context ·Donatella Marino, Clizia Zichi, (unknown), Elisa Sperti, Massimo Di Maïo	27
8	Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience 2019 ·Cancers ·Elisabetta Fenocchio, (unknown), (unknown), Roberto Filippi, Ilaria Depetris, (unknown), Pasquale Lombardi, Donatella Marino, Celeste Cagnazzo, (unknown), Marco Vaira, Massimo Aglietta, Francesco Leone	3
9	Emerging molecular target antagonists for the treatment of biliary tract cancer 2018 ·Expert Opinion on Emerging Drugs ·Pasquale Lombardi, Donatella Marino, Elisabetta Fenocchio, (unknown), Massimo Aglietta, Francesco Leone	14
10	“Shades of Gray” in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria 2018 ·Critical Reviews in Oncology/Hematology ·Pasquale Lombardi, Stefano Silvestri, Donatella Marino, (unknown), Donata Campra, Paolo De Paolis, Massimo Aglietta, Francesco Leone	4
11	Fluoropyrimidine-induced cardiotoxicity 2018 ·Critical Reviews in Oncology/Hematology ·Ilaria Depetris, Donatella Marino, Alessandro Bonzano, Celeste Cagnazzo, Roberto Filippi, Massimo Aglietta, Francesco Leone	56
12	Aflibercept efficacy according to sidedness, RAS and BRAF mutations. Findings from the VELOUR trial in second line therapy of advanced colorectal cancer patients 2017 ·Annals of Oncology ·Evaristo Maiello, Valentina Pomella, Pratyaksha Wirapati, Maria Di Bartolomeo, Maria Giulia Zampino, Francesco Leone, Tiziana Pia Latiano, Filippo Pietrantonio, Paola Simona Ravenda, Donatella Marino, Sabine Tejpar	4
13	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 2017 ·Critical Reviews in Oncology/Hematology ·Giuseppe Aprile, Francesca Negri, Francesco Giuliani, Elisa De Carlo, Davide Melisi, Francesca Simionato, Nicola Silvestris, Oronzo Brunetti, Francesco Leone, Donatella Marino, Daniele Santini, Emanuela Dell’Aquila, Tea Zeppola, Marco Puzzoni, Mario Scartozzi	23
14	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 2016 ·Targeted Oncology ·Marco Puzzoni, Nicola Silvestris, Francesco Leone, Riccardo Giampieri, Luca Faloppi, Laura Demurtas, Emanuela Dell’Aquila, Donatella Marino, Oronzo Brunetti, Silvio Ken Garattini, Elena Ongaro, Giorgio Astara, L. Orgiano, Giuseppe Aprile, Daniele Santini, Mario Scartozzi	15
15	Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer 2016 ·British Journal of Cancer ·Srinivasa R. Rao, (unknown), Donatella Marino, (unknown), Seint T. Lwin, Isabel R. Orriss, Freddie C. Hamdy, Claire M. Edwards	143
16	Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma 2015 ·Cancer Chemotherapy and Pharmacology ·Stefano Cereda, Michèle Milella, Stefano Cordio, Francesco Leone, Giuseppe Aprile, Antonella Galiano, Stefania Mosconi, Enrico Vasile, Daniele Santini, Carmen Belli, A. Auriemma, Anna Novarino, (unknown), (unknown), Donatella Marino, Stefania Eufemia Lutrino, (unknown), (unknown), Luca Aldrighetti, Michele Reni	12
17	Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology 2015 ·OncoTargets and Therapy ·Giuseppe Aprile, Francesco Leone, Mariaelena Casagrande, Donatella Marino, (unknown), (unknown), Luca Faloppi, Mario Scartozzi, Stefano Cascinu	4
18	A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study. 2015 ·Journal of Clinical Oncology ·Francesco Leone, Donatella Marino, Roberto Filippi, Stefano Cereda, Carmen Belli, Rosella Spadi, Guglielmo Nasti, Massimo Montano, Alessio Amatu, Giuseppe Aprile, Celeste Cagnazzo, Gianpiero Fasola, Salvatore Siena, Libero Ciuffreda, Michele Reni, Massimo Aglietta	3
19	Potentially resectable metastatic colorectal cancer: An individualized approach to conversion therapy 2014 ·Critical Reviews in Oncology/Hematology ·Donatella Marino, Francesco Leone, Francesca D’Avanzo, Dario Ribero, Lorenzo Capussotti, Massimo Aglietta	8
20	Biliary tract carcinomas: From chemotherapy to targeted therapy 2012 ·Critical Reviews in Oncology/Hematology ·Donatella Marino, Francesco Leone, Giuliana Cavalloni, Celeste Cagnazzo, Massimo Aglietta	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact